TSPO and schizophrenia: In this context a meta-analysis on TSPO-PET in schizophrenia reported that differences between patients and healthy subjects were only apparent from studies using [11C]PK11195, without any such difference evident in the studies using second-generation TSPO radioligands like [11C]PBR28 and [18F]FEPPA, noting that these findings were driven by small studies with low variability in outcomes (Marques et al., 2019).